144 related articles for article (PubMed ID: 22948082)
21. Comparison of the effects of two long-acting beta2-agonists on cytokine secretion by human airway epithelial cells.
Chiu JC; Hsu JY; Fu LS; Chu JJ; Chi CS
J Microbiol Immunol Infect; 2007 Oct; 40(5):388-94. PubMed ID: 17932597
[TBL] [Abstract][Full Text] [Related]
22. Downregulation by a long-acting beta2-adrenergic receptor agonist and corticosteroid of Staphylococcus aureus-induced airway epithelial inflammatory mediator production.
Fragaki K; Kileztky C; Trentesaux C; Zahm JM; Bajolet O; Johnson M; Puchelle E
Am J Physiol Lung Cell Mol Physiol; 2006 Jul; 291(1):L11-8. PubMed ID: 16489115
[TBL] [Abstract][Full Text] [Related]
23. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
Bousquet J; Boulet LP; Peters MJ; Magnussen H; Quiralte J; Martinez-Aguilar NE; Carlsheimer A
Respir Med; 2007 Dec; 101(12):2437-46. PubMed ID: 17905575
[TBL] [Abstract][Full Text] [Related]
24. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers.
Palmqvist M; Arvidsson P; Beckman O; Peterson S; Lötvall J
Pulm Pharmacol Ther; 2001; 14(1):29-34. PubMed ID: 11162416
[TBL] [Abstract][Full Text] [Related]
25. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the effects of budesonide/formoterol maintenance and reliever therapy with fluticasone/salmeterol fixed-dose treatment on airway inflammation and small airway impairment in patients who need to step-up from inhaled corticosteroid monotherapy.
Hozawa S; Terada M; Hozawa M
Pulm Pharmacol Ther; 2014 Apr; 27(2):190-6. PubMed ID: 24388868
[TBL] [Abstract][Full Text] [Related]
27. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
28. Induction of regulator of G-protein signaling 2 expression by long-acting β2-adrenoceptor agonists and glucocorticoids in human airway epithelial cells.
Holden NS; George T; Rider CF; Chandrasekhar A; Shah S; Kaur M; Johnson M; Siderovski DP; Leigh R; Giembycz MA; Newton R
J Pharmacol Exp Ther; 2014 Jan; 348(1):12-24. PubMed ID: 24163441
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells.
Yamaya M; Nishimura H; Deng X; Sugawara M; Watanabe O; Nomura K; Shimotai Y; Momma H; Ichinose M; Kawase T
Respir Investig; 2020 May; 58(3):155-168. PubMed ID: 32094077
[TBL] [Abstract][Full Text] [Related]
30. Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke.
MacRedmond RE; Greene CM; Dorscheid DR; McElvaney NG; O'Neill SJ
Respir Res; 2007 Nov; 8(1):84. PubMed ID: 18034897
[TBL] [Abstract][Full Text] [Related]
31. Inflammatory stimuli inhibit glucocorticoid-dependent transactivation in human pulmonary epithelial cells: rescue by long-acting beta2-adrenoceptor agonists.
Rider CF; King EM; Holden NS; Giembycz MA; Newton R
J Pharmacol Exp Ther; 2011 Sep; 338(3):860-9. PubMed ID: 21622733
[TBL] [Abstract][Full Text] [Related]
32. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction.
van der Woude HJ; Boorsma M; Bergqvist PB; Winter TH; Aalbers R
Pulm Pharmacol Ther; 2004; 17(2):89-95. PubMed ID: 15123230
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy: Synergistic suppression of virus-induced chemokines in airway epithelial cells.
Edwards MR; Johnson MW; Johnston SL
Am J Respir Cell Mol Biol; 2006 May; 34(5):616-24. PubMed ID: 16424382
[TBL] [Abstract][Full Text] [Related]
34. A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta-agonists for asthma maintenance treatment in Germany.
Aballéa S; Cure S; Vogelmeier C; Wirén A
Int J Clin Pract; 2008 Dec; 62(12):1870-9. PubMed ID: 18803555
[TBL] [Abstract][Full Text] [Related]
35. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice.
Tamm M; Richards DH; Beghé B; Fabbri L
Respir Med; 2012 Dec; 106 Suppl 1():S9-19. PubMed ID: 23273165
[TBL] [Abstract][Full Text] [Related]
36. Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy.
Cossette B; Beauchesne MF; Forget A; Lemière C; Larivée P; Rey E; Blais L
Ann Allergy Asthma Immunol; 2014 May; 112(5):459-64. PubMed ID: 24656659
[TBL] [Abstract][Full Text] [Related]
37. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
[TBL] [Abstract][Full Text] [Related]
38. Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol.
Blais L; Beauchesne MF; Forget A
Respir Med; 2009 Feb; 103(2):237-43. PubMed ID: 18930647
[TBL] [Abstract][Full Text] [Related]
39. The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells.
Horvath G; Mendes ES; Schmid N; Schmid A; Conner GE; Salathe M; Wanner A
J Allergy Clin Immunol; 2007 Nov; 120(5):1103-9. PubMed ID: 17920670
[TBL] [Abstract][Full Text] [Related]
40. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells.
Groskreutz DJ; Monick MM; Powers LS; Yarovinsky TO; Look DC; Hunninghake GW
J Immunol; 2006 Feb; 176(3):1733-40. PubMed ID: 16424203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
